Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan for Non-Coronary Obstructive Angina
NCT07392281Phase 1Recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of macitentan in Angina with non-obstructive coronary arteries (ANOCA), sponsored by China-Japan Friendship Hospital. Primary endpoints: Coronary Flow Reserve at 4 weeks and Index of Microcirculatory Resistance at 4 weeks. Started Sep 2025; status: recruiting.
02
Drugs
macitentan
03
Conditions
Angina with non-obstructive coronary arteries (ANOCA)
Beyond the preview
Go deeper on NCT07392281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07392281.